Control group (n = 52) | Aprepitant group (n = 54) | P-value | |
---|---|---|---|
Age (median, range) | 59 (29–83) | 58 (38–81) | 0.70 |
Performance status (ECOG) 0–1/2–3 | 51/1 | 53/1 | 1.00 |
Cancer diagnosis (number, %) | |||
Ovarian or tubal cancer | 17 (32.7) | 22 (40.7) | 0.43 |
Uterine cancer | 28 (53.8) | 28 (51.9) | 0.85 |
Cervical cancer | 6 (11.5) | 1 (1.9) | 0.06 |
Vaginal cancer | 0 (0) | 1 (1.9) | 1.00 |
Double cancer | 1 (1.9) | 2 (3.7) | 1.00 |
Staging (number, %) | |||
I/II/III | 39 (75.0) | 39 (72.2) | 0.83 |
IV/recurrence | 13 (25.0) | 15 (27.8) | |
Chemotherapy setting | |||
neoadjuvant or adjuvant | 44 (84.6) | 49 (90.7) | 0.34 |
for advanced cancer | 8 (15.4) | 5 (9.3) | |
Height (cm) (median, range) | 155.5 (144.6–172.1) | 154.2 (142.0–169.5) | 0.49 |
Body weight (kg) (median, range) | 54.7 (35.6–84.6) | 54.3 (37.7–89.2) | 0.79 |
Body surface area (m2) (median, range) | 1.53 (1.24–1.85) | 1.54 (1.21–1.87) | 0.90 |
Drinking habit (number, %) | 24 (46.2) | 21 (38.9) | 0.57 |
Carboplatin dosage (AUC) (number, %) | |||
5 | 52 (100) | 53 (98.1) | 1.00 |
6 | 0 (0) | 1 (1.9) | |
Paclitaxel dosage (mg) (median, range) | 261.7 (220–320) | 266.8 (210–325) | 0.43 |
Dose reduction (number, %) | 3 (5.8) | 1 (1.9) | 0.36 |
Renal dysfunction (number, %) | 4 (7.6) | 5 (9.3) | 1.00 |
Liver dysfunction (number, %) | 9 (17.3) | 12 (22.2) | 0.63 |